Trial Profile
A Randomized, Double-Masked, Placebo-Controlled Phase 1/2a Study of the Efficacy and Safety of Two Dosing Regimens of RVL-1201 in the Treatment of Acquired Blepharoptosis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 18 Nov 2021
Price :
$35
*
At a glance
- Drugs Oxymetazoline (Primary)
- Indications Blepharoptosis
- Focus Therapeutic Use
- Sponsors RevitaLid; RVL
- 17 Feb 2014 New trial record